Suggested remit - To appraise the clinical and cost effectiveness of treosulfan with fludarabine within its marketing authorisation as a conditioning treatment for non-malignant diseases prior to allogeneic haematopoietic stem cell transplantation.
Status Proposed
Process STA 2018
ID number 1540

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
24 January 2019 - 21 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance